BR112012017349A2 - "composição farmacêuticas de proteínas de igf-i, um tamponamento e um agente de tonicidade" - Google Patents

"composição farmacêuticas de proteínas de igf-i, um tamponamento e um agente de tonicidade"

Info

Publication number
BR112012017349A2
BR112012017349A2 BR112012017349A BR112012017349A BR112012017349A2 BR 112012017349 A2 BR112012017349 A2 BR 112012017349A2 BR 112012017349 A BR112012017349 A BR 112012017349A BR 112012017349 A BR112012017349 A BR 112012017349A BR 112012017349 A2 BR112012017349 A2 BR 112012017349A2
Authority
BR
Brazil
Prior art keywords
igf
tonicity agent
pharmaceutical compositions
protein
buffering
Prior art date
Application number
BR112012017349A
Other languages
English (en)
Inventor
Mahler Hanns-Christian
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of BR112012017349A2 publication Critical patent/BR112012017349A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

patente de invenção: "composições farmacêuticas de proteínas de igf-i, um tamponamento e um agente de tonicidade". a presente invenção refere-se a uma composição farmacêutica, compreendendo uma proteína de fator de crescimento de tipo insulina i (igf-i) como ingrediente farmacêutico (api), um agente de tonicidade e um tampão. essa composição pode ser administrada como injeção ou infusão e é especialmente últil para o tratamento, prevenção e/ou atraso de progressão de desordens neurodegenerativas, em particular doença de alzheimer (ad), uma doença de neurônio motor (mnd), em particular esclerose lateral amiotrófica (als) ou atrofia muscualr espinhal (sma) ou uma distrofia muscular (md), em particular distrofia muscular de duchenne (dmd) ou distrofia miotônica (mmd).
BR112012017349A 2009-12-23 2010-12-20 "composição farmacêuticas de proteínas de igf-i, um tamponamento e um agente de tonicidade" BR112012017349A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP09180607 2009-12-23
PCT/EP2010/070174 WO2011076702A1 (en) 2009-12-23 2010-12-20 Pharmaceutical compositions comprising igf-1 proteins, a buffering and a tonicity agent

Publications (1)

Publication Number Publication Date
BR112012017349A2 true BR112012017349A2 (pt) 2017-06-13

Family

ID=43598371

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012017349A BR112012017349A2 (pt) 2009-12-23 2010-12-20 "composição farmacêuticas de proteínas de igf-i, um tamponamento e um agente de tonicidade"

Country Status (10)

Country Link
US (1) US20110152188A1 (pt)
EP (1) EP2515868A1 (pt)
JP (1) JP2013514340A (pt)
KR (1) KR20120106854A (pt)
CN (1) CN102665682A (pt)
BR (1) BR112012017349A2 (pt)
CA (1) CA2780080A1 (pt)
MX (1) MX2012007102A (pt)
RU (1) RU2012130606A (pt)
WO (1) WO2011076702A1 (pt)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120294866A1 (en) * 2010-01-19 2012-11-22 F. Hoffmann-La Roche Ag Pharmaceutical formulation for proteins
WO2012048330A2 (en) * 2010-10-08 2012-04-12 The Mclean Hospital Corporation Treatment of motor neuron disease
ES2872998T3 (es) 2013-12-19 2021-11-03 Puretein Bioscience Llc Procedimientos de tratamiento de animales
AR103173A1 (es) 2014-12-22 2017-04-19 Novarits Ag Productos farmacéuticos y composiciones líquidas estables de anticuerpos il-17
DK3328416T5 (da) 2015-07-30 2024-10-07 Biomarin Pharm Inc Anvendelse af natriuretske peptidvarianter af c-typen til behandling af skeletdysplasi
RS64263B1 (sr) * 2015-08-19 2023-07-31 Astrazeneca Ab Stabilna anti-ifnar1 formulacija
CN112020365A (zh) * 2018-01-26 2020-12-01 豪夫迈·罗氏有限公司 组合物和使用方法
AU2023210427A1 (en) * 2022-01-19 2024-08-22 Oak Hill Bio Limited Compositions and methods for reducing oxidation of igf‐1/igfbp
WO2025229980A1 (ja) * 2024-05-01 2025-11-06 Ｊｃｒファーマ株式会社 凍結乾燥製剤

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ207842A (en) 1983-04-25 1988-02-12 Chiron Corp Production of human insulin-like growth factor (igf) using cdna
IL71991A (en) 1983-06-06 1994-05-30 Genentech Inc Preparation of human FGI and FGE in their processed form through recombinant AND tranology in prokaryotes
US4904584A (en) * 1987-12-23 1990-02-27 Genetics Institute, Inc. Site-specific homogeneous modification of polypeptides
US6235488B1 (en) * 1988-09-29 2001-05-22 Agilent Technologies, Inc. Surface preparation for chemical-specific binding
US5158875A (en) * 1989-08-25 1992-10-27 Amgen Inc. Production of biologically active insulin-like growth factor i from high expression host cell systems
NZ236819A (en) * 1990-02-03 1993-07-27 Max Planck Gesellschaft Enzymatic cleavage of fusion proteins; fusion proteins; recombinant dna and pharmaceutical compositions
US5126324A (en) * 1990-06-07 1992-06-30 Genentech, Inc. Method of enhancing growth in patients using combination therapy
US5681814A (en) * 1990-06-07 1997-10-28 Genentech, Inc. Formulated IGF-I Composition
EP0597033B1 (en) 1991-08-01 1997-04-09 Genentech, Inc. Igf-1 to improve the neural condition
US5861373A (en) * 1991-08-01 1999-01-19 Genentech, Inc IGF-1 to improve the neural condition
SE9300105D0 (sv) * 1993-01-15 1993-01-15 Kabi Pharmacia Ab Stable protein solution
US5824784A (en) * 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
US5932462A (en) * 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
US5672662A (en) * 1995-07-07 1997-09-30 Shearwater Polymers, Inc. Poly(ethylene glycol) and related polymers monosubstituted with propionic or butanoic acids and functional derivatives thereof for biotechnical applications
JP2001511162A (ja) * 1997-02-06 2001-08-07 ノボ ノルディスク アクティーゼルスカブ 付加され、そして／又は除去された付着基を有するポリペプチド−ポリマー結合体
US6767892B1 (en) * 1997-11-07 2004-07-27 Chrion Corporation Compositions providing for increased IGF-I solubility
JP2001522813A (ja) * 1997-11-07 2001-11-20 カイロン コーポレイション 新規のｉｇｆ−ｉ組成物およびその使用
US7067485B2 (en) * 1997-11-07 2006-06-27 Chiron Corporation IGF-I composition and its use
WO1999055362A1 (en) * 1998-04-29 1999-11-04 Genentech, Inc. Spray dried formulations of igf-i
US6436897B2 (en) * 1998-06-01 2002-08-20 Celtrix Pharmaceuticals, Inc. Pharmaceutical formulations for IGF/IGFBP
AU762351B2 (en) * 1999-01-06 2003-06-26 Genentech Inc. Insulin-like growth factor (IGF) I mutant variants
JP2002535967A (ja) * 1999-01-06 2002-10-29 ジェネンテック・インコーポレーテッド インシュリン様成長因子（ｉｇｆ）ｉ変異体
AU763039B2 (en) * 1999-04-08 2003-07-10 Genentech Inc. Composition based on oppositely-charged polypeptides
US6596849B1 (en) * 1999-05-28 2003-07-22 Academia Sinica Monoclonal-antibody for analysis and clearance of polyethylene glycol and polyethylene glycol-modified molecules
US7431921B2 (en) * 1999-08-27 2008-10-07 Maxygen Aps Interferon beta-like molecules
US20040014652A1 (en) * 2000-06-01 2004-01-22 Andre Trouet Tumor activated prodrug compounds and methods of making and using the same
US20020082215A1 (en) 2000-10-13 2002-06-27 Chiron Corporation Method for treating ischemic events affecting the central nervous system
EP1674113A1 (en) 2004-12-22 2006-06-28 F. Hoffmann-La Roche Ag Conjugates of insulin-like growth factor-1 (IGF-1) and poly(ethylene glycol)
BRPI0620316A2 (pt) * 2005-12-21 2011-11-08 Wyeth Corp formulações de proteìnas com viscosidades reduzida e seus usos
CL2007002502A1 (es) 2006-08-31 2008-05-30 Hoffmann La Roche Variantes del factor de crecimiento similar a insulina-1 humano (igf-1) pegilados en lisina; metodo de produccion; proteina de fusion que la comprende; y su uso para tratar la enfermedad de alzheimer.
JP5173018B2 (ja) * 2008-04-03 2013-03-27 エフ．ホフマン−ラ ロシュ アーゲー 神経筋障害の処置のためのｐｅｇ化ｉｇｆ−ｉ変異体の使用

Also Published As

Publication number Publication date
CN102665682A (zh) 2012-09-12
WO2011076702A1 (en) 2011-06-30
KR20120106854A (ko) 2012-09-26
RU2012130606A (ru) 2014-01-27
US20110152188A1 (en) 2011-06-23
MX2012007102A (es) 2012-07-23
EP2515868A1 (en) 2012-10-31
JP2013514340A (ja) 2013-04-25
CA2780080A1 (en) 2011-06-30

Similar Documents

Publication Publication Date Title
BR112012017349A2 (pt) "composição farmacêuticas de proteínas de igf-i, um tamponamento e um agente de tonicidade"
GEP20125628B (en) Pharmaceutical compositions containing antagonist anti-cd40 antibody
PE20091715A1 (es) Variantes de igf-i pegiladas y composiciones que las contienen
WO2008118017A3 (en) Prame derived peptides and immunogenic compositions comprising these
TN2011000209A1 (en) Aryl methyl benzoquinazolinone m1 receptor positive allosteric modulators
PE20230819A1 (es) Composiciones y usos de glp-1
BRPI0705488A (pt) composição nanoparticulada estável, métodos de preparar a mesma e de prevenir e/ou tratar uma infecção bacteriana, composição farmacêutica, e, forma de dosagem
JP7608342B2 (ja) 治療用組成物
WO2010051918A3 (en) Compositions containing lipid micro- or nanoparticles for the enhancement of the dermal action of solid particles
MX349054B (es) Leptinas altamente solubles.
TN2012000231A1 (en) Quinoline amide m1 receptor positive allosteric modulators
BR112013020586A2 (pt) Uso de células derivadas de tecido do cordão umbilical
WO2008092006A3 (en) Antimicrobial compositions
WO2012075081A3 (en) High-strength testosterone undecanoate compositions
ATE530544T1 (de) Benzyl-substituierte positive allosterische chinolon-m1-rezeptormodulatoren
PE20110302A1 (es) Formulacion farmaceutica de un anticuerpo contra p-selectina
BR112013033008A8 (pt) composição farmacêutica líquida compreendendo nitisinona
WO2011107436A3 (en) Aqueous clear solutions of fluocinolone acetonide for treatment of otic inflammation
WO2009043987A9 (fr) Compositions antibiotiques a base d'huiles essentielles - prophylaxie et traitement d'infections nosocomiales
WO2006078424A3 (en) Polyherbal compositions and methods for treating viral infections
WO2013130577A3 (en) Compositions and methods for the treatment of migraine
BR112012019921A2 (pt) composições líquidas compreendendo um agente de resfriamento não-metol e um espessante para tratamento de um sintoma respiratório.
MX2014013091A (es) Composicion farmaceutica.
BR112012022209A2 (pt) composições farmacêuticas compreendendo monoterpenos
PE20150345A1 (es) Nuevo compuesto que tiene la capacidad para inhibir la enzima deshidrogenasa 11b-hidroxiesteroide tipo 1 (11b-hsd1) o sal farmaceuticamente aceptable del mismo, metodo para producir el mismo, y composicion farmaceutica que contiene el mismo como ingrediente activo

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]